4.7 Review

Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety

期刊

JOURNAL OF MEDICAL VIROLOGY
卷 94, 期 6, 页码 2369-2375

出版社

WILEY
DOI: 10.1002/jmv.27590

关键词

booster vaccination; COVID-19; heterologous vaccination; SARS-CoV-2; vaccine

类别

资金

  1. key project of provincial ministry coconstruction, Health Science and Technology project plan of Zhejiang Province [WKJ-ZJ-2128]
  2. Key Laboratory of Women's Reproductive Health Research of Zhejiang Province [ZDFY2020-RH-0006]
  3. National Natural Science Foundation of China [U20A20351]
  4. Key Research and Development Plan of Zhejiang Province [2021C03079]

向作者/读者索取更多资源

It is necessary to implement a booster vaccination strategy for COVID-19 based on existing data. However, not all individuals require an additional dose of vaccine six months after the initial immunization. Priority should be given to high-risk groups such as the elderly and immunocompromised individuals. Heterologous boosters can induce stronger immune responses and enhance immune protection, but further scientific data and clinical studies are needed to verify safety.
At present, the global COVID-19 epidemic has not been completely controlled, and epidemic prevention and control still face severe challenges. As there is no specific treatment for COVID-19, promoting roll-out vaccinations and building herd immunity are still the most effective and economic measures to control the COVID-19 pandemic. However, the neutralizing antibody level in the recipients decreases with time, and the vaccine's protective efficacy gradually weakens. It is still inconclusive whether it is necessary to carry out booster vaccination to strengthen the immune barrier to infection. In this paper, we combined the existing data on the effectiveness and persistence of COVID-19 vaccines. We found that it is necessary to carry out a booster vaccination strategy. However, not all subjects need to receive one more dose of vaccine 6 months after the initial immunization. Priority should be given to the high-risk groups, such as the elderly and people with immunodeficiency. A heterologous booster can induce higher immune responses and enhance immune protection than homologous vaccinations. However, more scientific data and clinical studies are needed to verify the safety of heterologous vaccination strategies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据